A new initiative hopes to increase the number of people participating in dementia clinical trials in the UK, aiming to identify tens of thousands of potential trial participants. 

The new ‘Dementia Trials Accelerator’ initiative hopes to address pharma-identified roadblocks to the delivery of commercial clinical trials in the UK identified by Lord O’Shaughnessy in the Independent Review of commercial clinical trials in the UK. 

It will establish a large group of eligible people who are at risk of or diagnosed with early-stage dementia who would benefit from access to clinical trials. 

Spearheaded by two national research institutes, the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK), and funded by the Medical Research Council (MRC), the Accelerator is supported by the government’s Dame Barbara Windsor Dementia Goals programme (formerly known as the Dame Barbara Windsor Dementia Mission).  

Professor Andrew Morris, Director of Health Data Research UK, said: “Today’s research is tomorrow’s care. By harnessing cutting-edge technology and the power of health data, the Dementia Trials Accelerator will unite industry, academic and clinical expertise from around the UK to significantly boost our ability to run efficient, large-scale trials, giving more people quicker access to potentially life-changing treatments.” 

Improving access and diversity of dementia trials 

The Dementia Trials Accelerator comprises five objectives: 

1: Reducing high screening failure rates by creating a ‘Biomarker Minimum Toolbox’. Incorporating genetic risk scores, blood biomarkers, and clinical measurements, toolbox will accurately identify individuals at risk of progression to dementia. 

  1. Capitalise on existing UK cohorts such as to assemble a novel pre-screened trial-ready cohort, expediting recruitment and facilitating scalability.
  2. Accelerate low-cost delivery through innovative, community-based methodologies. Embracing digital technology and hybrid delivery models to streamline delivery and improve participation. Input from patients themselves will be integral to ensure the widest possible access.
  3. Assemble a UK-wide AI-enabled data platform to integrate diverse data sets and accelerate collaborative research in neurodegeneration.
  4. Prioritise the needs of industry innovators as well as patients and the public through an iterative approach to stakeholder design and dialogue.

Hilary Evans-Newton, Co-Chair of the Dame Barbara Windsor Dementia Goals programme, said: “Since 2012, recruitment for late-stage dementia trials has consistently lagged behind cancer research, leaving crucial gaps in our understanding of this devastating condition. Right now, only 2% of people with a dementia diagnosis in the UK are signed up to hear about clinical trials, and many studies fail to represent the diversity of people affected. Women, people from African-Caribbean and South Asian communities, and those with Down’s Syndrome, who are disproportionately impacted by dementia, are often not accounted for.  

“The Dame Barbara Windsor Dementia Goals programme was established to ensure that more people with dementia in the UK benefit from clinical trials, at the same time as fuelling economic growth by advancing the UK’s life sciences sector. The Dementia Trials Accelerator will help bring us one step closer to achieving that goal.”